emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Efinopegdutide' with aliases JNJ-64565111, HM12525A, LAPSGLP/GCG, MK-6024 · 2026-09-27 12:04 · somebody
kind set kind set to protein: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: Efinopegdutide is a GLP-1 and glucagon receptor co-agonist given by subcutaneous injection once a week. · 2026-09-27 12:04 · somebody
fact added summary: In a 24-week phase IIa study in non-alcoholic fatty liver disease, liver fat fell by 72.7% from baseline with efinopegdu · 2026-09-27 12:04 · somebody
citation added pmid 37355043 cited as emerging: Efinopegdutide reduced liver fat content more than semaglutide over 24 weeks in NAFLD (phase IIa) · 2026-09-27 12:04 · somebody
question added Have longer trials measured liver outcomes beyond fat content, such as fibrosis, with efinopegdutide? · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.